[1] WEN J, XUAN B, LIU Y, et al. Updating the NLRC4 inflammasome: from bacterial infections to autoimmunity and cancer[J]. Front Immunol, 2021, 12: 702527.
[2] DUBEY S R, TURNBULL C, PANDEY A, et al. Molecular mechanisms and regulation of inflammasome activation and signaling: sensing of pathogens and damage molecular patterns[J]. Cell Mol Immunol, 2025, 22(11): 1313-1344.
[3] KAY C, WANG R, KIRKBY M, et al. Molecular mechanisms activating the NAIP-NLRC4 inflammasome: implications in infectious disease, autoinflammation, and cancer[J]. Immunol Rev, 2020, 297(1): 67-82.
[4] WILLEMSEN M, ROOSENS W, STAELS F, et al. NLRC4-associated autoinflammatory disease: insights from mouse models and somatic variants[J]. J Allergy Clin Immunol, 2025, 155(3): 803-807.
[5] SONG L, LUO Z Q. Post-translational regulation of ubiquitin signaling[J]. J Cell Biol, 2019, 218(6): 1776-1786.
[6] TOMA-FUKAI S, SHIMIZU T. Structural diversity of ubiquitin E3 ligase[J]. Molecules, 2021, 26(21): 6682.
[7] BHATS A, VASI Z, ADHIKARI R, et al. Ubiquitin proteasome system in immune regulation and therapeutics[J]. Curr Opin Pharmacol, 2022, 67: 102310.
[8] LIU W, LIU X, LI Y, et al. LRRK2 promotes the activation of NLRC4 inflammasome during salmonella typhimurium infection[J]. J Exp Med, 2017, 214(10): 3051-3066.
[9] GUAN C, HUANG X, YUE J, et al. SIRT3-mediated deacetylation of NLRC4 promotes inflammasome activation[J]. Theranostics, 2021, 11(8): 3981-3995.
[10] WANG Z, NIU K, LIU W, et al. ER-phagy activation by AMFR attenuates cardiac fibrosis post-myocardial infarction via mTORC1 pathway[J]. Adv Sci, 2025, 12(37): e04552.
[11] GAVALI S, LIU J, LI X, et al. Ubiquitination in T-cell activation and checkpoint inhibition: new avenues for targeted cancer immunotherapy[J]. Int J Mol Sci, 2021, 22(19): 10800.
[12] SU S, TIAN R, JIAO Y, et al. Ubiquitination and deubiquitination: implications for the pathogenesis and treatment of osteoarthritis[J]. J Orthop Translat, 2024, 49: 156-166.
[13] ZHENG N, SHABEK N. Ubiquitin ligases: structure, function, and regulation[J]. Annu Rev Biochem, 2017, 86: 129-157.
[14] DANG F, NIE L, WEI W. Ubiquitin signaling in cell cycle control and tumorigenesis[J]. Cell Death Differ, 2021, 28(2): 427-438.
[15] TOKUNAGA F, IKEDA F. Linear ubiquitination in immune and neurodegenerative diseases, and beyond[J]. Biochem Soc Trans, 2022, 50(2): 799-811.
[16] LEE Y, YOON B, SON S, et al. Inhibition of immunoproteasome attenuates NLRP3 inflammasome response by regulating E3 ubiquitin ligase TRIM31[J]. Cells, 2024, 13(8): 675.
[17] ZHAO Y, MIAO C, WANG R, et al. Jianpi antai formula prevents miscarriage by repressing M1 polarization of decidual macrophages through ubiquitination of NLRP3 mediated by MARCH7[J]. J Eth-nopharmacol, 2024, 324: 117796.
[18] BEESETTI S. Ubiquitin ligases in control: regulating NLRP3 inflammasome activation[J]. Front Biosci (Landmark Ed), 2025, 30(3): 25970.
[19] YALCINKAYA M, LIU W, THOMAS L A, et al. BRCC3-mediated NLRP3 deubiquitylation promotes inflammasome activation and atherosclerosis in Tet2 clonal hematopoiesis[J]. Circulation, 2023, 148(22): 1764-1777.
[20] JOSHI V, UPADHYAY A, KUMAR A, et al. Gp78 E3 ubiquitin ligase: essential functions and contributions in proteostasis[J]. Front Cell Neurosci, 2017, 11: 259.
[21] ZHANG H, WEI R, YANG X, et al. AMFR drives allergic asthma development by promoting alveolar macrophage-derived GM-CSF production[J]. J Exp Med, 2022, 219(5): e20211828.
[22] GONZ?魣LEZ A, COVARRUBIAS-PINTO A, BHASKARA R M, et al. Ubiquitination regulates ER-phagy and remodelling of endoplasmic reticulum[J]. Nature, 2023, 618(7964): 394-401.
[23] ZHANG J, LIU C, LIU J, et al. The autocrine motility factor receptor delays the pathological progression of Alzheimer′s disease via regulating the ubiquitination-mediated degradation of APP[J]. Alzheimer′s Res Ther, 2025, 17: 95.
[24] SHEN C, PANDEY A, ENOSI TUIPULOTU D, et al. Inflammasome protein scaffolds the DNA damage complex during tumor development[J]. Nat Immunol, 2024, 25(11): 2085-2096.
[25] DOMBLIDES C, CRAMPTON S, LIU H, et al. Human NLRC4 expression promotes cancer survival and associates with type I interferon signaling and immune infiltration[J]. J Clin Invest, 2024, 134(11): e166085.